📇 Rhumatologue · CHAMBRAY LES TOURS · (37) · Hospitalier

MME ANNABEL MARUANI

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Expérience confirmée
16 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
131.9 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CHAMBRAY LES TOURS (37)HospitalierRPPS 10002097755

EnseignementExpérience confirmée

16ans d'exercice (thèse 2010)

🇫🇷 Publications académiques françaises (8)🎓 2 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial

JAMA dermatology · 2021

📚 98 citations🎯 RCR 7.14Top 4% NIH🩺 Clinique🔓 Open Access

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases

The journal of allergy and clinical immunology. In practice · 2022

📚 25 citations🎯 RCR 3.91Top 11% NIH🔓 Open Access📄 PDF gratuit ↗

Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts' Opinion and Systematic Review from the Literature

Dermatology (Basel, Switzerland) · 2023

📚 10 citations🎯 RCR 1.28🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Background: Vascular anomalies (VAs) are increasingly being treated with PI3K/AKT/mTOR pathway inhibitors. These drugs have immunosuppressive properties and thus theoretically overexpose patients to opportunistic infections, especially Pneumocystis jirovecii pneumonia (PJP). PJP prophylaxis use lacks consensus. We aimed to investigate the prevalence of PJP in patients receiving mTOR/PI3K/AKT inhibitors for VAs and determine any indication for pneumocystis prophylaxis in this population. Methods: The study was conducted in 2 parts: (1) we sent a survey to a panel of international experts of VAs asking about their use of pneumocystis prophylaxis drugs and (2) we performed a systematic review of the literature of all published cases of patients receiving these drugs for VA to estimate the prevalence of PJP in this population. Results: Answers from 68 experts were analyzed: 21 (30.9%) answered they always add PJP prophylaxis when prescribing mTOR inhibitors, 20 (29.4%) case-by-case, and 27 (39.7%) never. For the systematic review, among 3,053 reports screened, 217 were included involving 1,189 patients (1,143 received sirolimus, 38 everolimus, 4 alpelisib, 4 miransertib). Among the 1,189 cases, 2 (0.2%) PJP were reported: one under sirolimus and one under everolimus. Thus, the prevalence of PJP was estimated at 0.88 cases/1,000 patients under sirolimus (95% CI: −0.84 to 2.59) and 26.31 cases/1,000 under everolimus (95% CI: −24.58 to 77.18). Patients with PJP never received prophylaxis drugs. We found no PJP cases under alpelisib and miransertib. PJP prophylaxis was given in 218 (18.3%) cases, more frequently for children (91.3 vs. 77.2% in the non-prophylaxis group, p = 0.012), mostly trimethoprim-sulfamethoxazole (186 patients, 85.3%). Conclusion: Our study shows that even if PJP is a rare event, it may occur in patients with VAs treated with an mTOR inhibitor. Although our results cannot allow for revising guidelines, prophylaxis with TMP-SMX might be appropriate for a subgroup of patients with risk factors for PJP.

Cookies & analyse de trafic

MME ANNABEL MARUANI

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal23

Pédiatrie14

Essai clinique8

Revue générale6

Revue / méta-analyse5

Qualité de vie / PROMs2

Recommandations2

Vraie vie / RWE2

Case report / série1

Épidémiologie & registres1

Lupus1

Pharmacovigilance1

Datasets & protocoles partagés

Partager cette fiche